IL215079A - A pharmacological preparation containing colchicine or thiocholchicine for the treatment of a thriving disease - Google Patents

A pharmacological preparation containing colchicine or thiocholchicine for the treatment of a thriving disease

Info

Publication number
IL215079A
IL215079A IL215079A IL21507911A IL215079A IL 215079 A IL215079 A IL 215079A IL 215079 A IL215079 A IL 215079A IL 21507911 A IL21507911 A IL 21507911A IL 215079 A IL215079 A IL 215079A
Authority
IL
Israel
Prior art keywords
thiocolchicine
colchicine
treating
pharmaceutical composition
proliferative disease
Prior art date
Application number
IL215079A
Other languages
English (en)
Hebrew (he)
Other versions
IL215079A0 (en
Original Assignee
Abraxis Bioscience Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abraxis Bioscience Llc filed Critical Abraxis Bioscience Llc
Publication of IL215079A0 publication Critical patent/IL215079A0/en
Publication of IL215079A publication Critical patent/IL215079A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51Nanocapsules; Nanoparticles
    • A61K9/5107Excipients; Inactive ingredients
    • A61K9/513Organic macromolecular compounds; Dendrimers
    • A61K9/5169Proteins, e.g. albumin, gelatin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/54Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Optics & Photonics (AREA)
  • Nanotechnology (AREA)
  • Dermatology (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL215079A 2009-03-13 2011-09-11 A pharmacological preparation containing colchicine or thiocholchicine for the treatment of a thriving disease IL215079A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21007409P 2009-03-13 2009-03-13
PCT/US2010/027159 WO2010105172A1 (en) 2009-03-13 2010-03-12 Combination therapy with thiocolchicine derivatives

Publications (2)

Publication Number Publication Date
IL215079A0 IL215079A0 (en) 2011-11-30
IL215079A true IL215079A (en) 2016-11-30

Family

ID=42728818

Family Applications (1)

Application Number Title Priority Date Filing Date
IL215079A IL215079A (en) 2009-03-13 2011-09-11 A pharmacological preparation containing colchicine or thiocholchicine for the treatment of a thriving disease

Country Status (12)

Country Link
US (2) US20120189701A1 (OSRAM)
EP (1) EP2405750B1 (OSRAM)
JP (1) JP5725563B2 (OSRAM)
KR (1) KR101739598B1 (OSRAM)
CN (1) CN102427728A (OSRAM)
AU (2) AU2010224012B2 (OSRAM)
BR (1) BRPI1008955A2 (OSRAM)
CA (1) CA2755121A1 (OSRAM)
IL (1) IL215079A (OSRAM)
MX (1) MX2011009452A (OSRAM)
NZ (1) NZ595189A (OSRAM)
WO (1) WO2010105172A1 (OSRAM)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8853260B2 (en) 1997-06-27 2014-10-07 Abraxis Bioscience, Llc Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
EP2359859A1 (en) 2002-12-09 2011-08-24 Abraxis BioScience, LLC Compositions comprising albumin nanoparticles and methods of delivery of pharmacological agents
US8735394B2 (en) * 2005-02-18 2014-05-27 Abraxis Bioscience, Llc Combinations and modes of administration of therapeutic agents and combination therapy
CA2598239C (en) 2005-02-18 2019-10-29 Abraxis Bioscience, Inc. Nanoparticulate formulations of taxanes and carrier proteins for use in combination chemotherapy
US7771751B2 (en) 2005-08-31 2010-08-10 Abraxis Bioscience, Llc Compositions comprising poorly water soluble pharmaceutical agents and antimicrobial agents
DK2117520T3 (en) 2006-12-14 2019-01-07 Abraxis Bioscience Llc BREAST CANCER THERAPY BASED ON HORMON RECEPTOR STATUS WITH NANOPARTICLES INCLUDING TAXAN
LT2481409T (lt) * 2007-03-07 2018-10-25 Abraxis Bioscience, Llc Nanodalelės, apimančios rapamiciną ir albuminą, kaip priešvėžinį agentą
DK2155188T3 (da) * 2007-06-01 2013-11-04 Abraxis Bioscience Llc Fremgangsmåder og sammensætninger til behandling af tilbagevendende kræft
AU2010236382B2 (en) 2009-04-15 2016-01-14 Abraxis Bioscience, Llc Prion-free nanoparticle compositions and methods
NZ602382A (en) 2010-03-26 2014-11-28 Abraxis Bioscience Llc Methods of treatment of hepatocellular carcinoma
ES2600912T3 (es) 2010-03-29 2017-02-13 Abraxis Bioscience, Llc Métodos para tratar el cáncer
MX2012011155A (es) 2010-03-29 2012-12-05 Abraxis Bioscience Llc Metodos para mejorar suministros de farmacos y efectividad de agentes terapeuticos.
WO2011153010A1 (en) 2010-06-04 2011-12-08 Abraxis Biosciences, Llc Methods of treatment of pancreatic cancer
JP6038123B2 (ja) 2011-04-28 2016-12-07 アブラクシス バイオサイエンス, エルエルシー ナノ粒子組成物の脈管内送達およびそれらの使用
SI2790675T1 (sl) 2011-12-14 2019-11-29 Abraxis Bioscience Llc Uporaba polimernih pomožnih snovi za liofilizacijo ali zamrzovanje delcev
EP2903610B1 (en) 2012-10-01 2021-11-03 Mayo Foundation For Medical Education And Research Cancer treatments
US9149455B2 (en) 2012-11-09 2015-10-06 Abraxis Bioscience, Llc Methods of treating melanoma
US9511046B2 (en) 2013-01-11 2016-12-06 Abraxis Bioscience, Llc Methods of treating pancreatic cancer
EP3698784A1 (en) 2013-03-12 2020-08-26 Abraxis BioScience, LLC Methods of treating lung cancer
CN110934852A (zh) 2013-03-14 2020-03-31 阿布拉科斯生物科学有限公司 治疗膀胱癌的方法
EP2924022A1 (en) * 2014-03-27 2015-09-30 INDENA S.p.A. Amorphous form of a thiocolchicine derivative
US20160143866A1 (en) * 2014-11-21 2016-05-26 Eli D. Ehrenpreis Combination Therapy for Administration of Monoclonal Antibodies
US10705070B1 (en) 2015-03-05 2020-07-07 Abraxis Bioscience, Llc Methods of assessing suitability of use of pharmaceutical compositions of albumin and poorly water soluble drug
US10527604B1 (en) 2015-03-05 2020-01-07 Abraxis Bioscience, Llc Methods of assessing suitability of use of pharmaceutical compositions of albumin and paclitaxel
CN116585310A (zh) 2015-06-29 2023-08-15 阿布拉科斯生物科学有限公司 治疗上皮样细胞肿瘤的方法
KR101748120B1 (ko) * 2015-07-13 2017-06-16 서울대학교산학협력단 나노입자-유리체 기반 단백질 복합체를 유효성분으로 포함하는 혈관신생억제용 조성물 및 이의 용도
AU2019239953B2 (en) 2018-03-20 2025-01-02 Abraxis Bioscience, Llc Methods of treating central nervous system disorders via administration of nanoparticles of an mtor inhibitor and an albumin
EP4051241A4 (en) 2019-10-28 2023-12-06 Abraxis BioScience, LLC PHARMACEUTICAL COMPOSITIONS OF ALBUMIN AND RAPAMYCIN

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6582959B2 (en) 1991-03-29 2003-06-24 Genentech, Inc. Antibodies to vascular endothelial cell growth factor
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
US6096331A (en) 1993-02-22 2000-08-01 Vivorx Pharmaceuticals, Inc. Methods and compositions useful for administration of chemotherapeutic agents
US5916596A (en) 1993-02-22 1999-06-29 Vivorx Pharmaceuticals, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
US6537579B1 (en) 1993-02-22 2003-03-25 American Bioscience, Inc. Compositions and methods for administration of pharmacologically active compounds
US6749868B1 (en) 1993-02-22 2004-06-15 American Bioscience, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
US20020032315A1 (en) 1997-08-06 2002-03-14 Manuel Baca Anti-vegf antibodies
US6884879B1 (en) 1997-04-07 2005-04-26 Genentech, Inc. Anti-VEGF antibodies
WO1998045331A2 (en) 1997-04-07 1998-10-15 Genentech, Inc. Anti-vegf antibodies
US6797691B1 (en) 1997-07-23 2004-09-28 Northwestern University Methods and compositions for inhibiting angiogenesis
KR20010085261A (ko) 1998-05-29 2001-09-07 빙검 더글라스 에이. 티로신 키나제 Src를 사용하는, 맥관형성의 조절에유용한 방법 및 조성물
EP1171117A4 (en) 1999-04-22 2002-08-07 American Bioscience Inc LONG-TERM ADMINISTRATION OF PHARMACOLOGICALLY ACTIVE AGENTS
IT1318401B1 (it) * 2000-03-17 2003-08-25 Indena Spa Derivati di n-desacetiltiocolchicina e composizioni farmaceutiche cheli contengono.
US20040143004A1 (en) 2002-02-26 2004-07-22 Joseph Fargnoli Metronomic dosing of taxanes
ES2428354T3 (es) 2002-09-18 2013-11-07 Trustees Of The University Of Pennsylvania Rapamicina para usar en la inhibición o prevención de la neovascularización coroidea
EP2359859A1 (en) 2002-12-09 2011-08-24 Abraxis BioScience, LLC Compositions comprising albumin nanoparticles and methods of delivery of pharmacological agents
WO2005117876A1 (en) 2004-06-01 2005-12-15 University Of Virginia Patent Foundation Dual small molecule inhibitors of cancer and angiogenesis
CA2598239C (en) * 2005-02-18 2019-10-29 Abraxis Bioscience, Inc. Nanoparticulate formulations of taxanes and carrier proteins for use in combination chemotherapy
US20070166388A1 (en) * 2005-02-18 2007-07-19 Desai Neil P Combinations and modes of administration of therapeutic agents and combination therapy
AU2006284657B2 (en) 2005-08-31 2012-07-19 Abraxis Bioscience, Llc Compositions and methods for preparation of poorly water soluble drugs with increased stability
US20080280987A1 (en) 2006-08-31 2008-11-13 Desai Neil P Methods of inhibiting angiogenesis and treating angiogenesis-associated diseases
US20100166869A1 (en) 2007-05-03 2010-07-01 Desai Neil P Methods and compositions for treating pulmonary hypertension
CN101077335A (zh) * 2007-06-29 2007-11-28 济南康泉医药科技有限公司 一种含酪氨酸激酶抑制剂的抗癌组合物

Also Published As

Publication number Publication date
JP2012520323A (ja) 2012-09-06
KR101739598B1 (ko) 2017-06-08
JP5725563B2 (ja) 2015-05-27
US20120189701A1 (en) 2012-07-26
BRPI1008955A2 (pt) 2015-09-01
MX2011009452A (es) 2011-11-29
CN102427728A (zh) 2012-04-25
AU2016208343A1 (en) 2016-08-18
AU2010224012B2 (en) 2016-04-28
EP2405750A4 (en) 2014-01-15
EP2405750A1 (en) 2012-01-18
CA2755121A1 (en) 2010-09-16
US20170105951A1 (en) 2017-04-20
AU2010224012A1 (en) 2011-11-03
IL215079A0 (en) 2011-11-30
KR20110128339A (ko) 2011-11-29
NZ595189A (en) 2013-08-30
WO2010105172A1 (en) 2010-09-16
EP2405750B1 (en) 2018-05-09

Similar Documents

Publication Publication Date Title
IL215079A (en) A pharmacological preparation containing colchicine or thiocholchicine for the treatment of a thriving disease
IL207128A0 (en) Pharmaceutical dosage form
ZA201107776B (en) Pharmaceutical composition
ZA201102406B (en) Pharmaceutical composition for modified release
AP2010005341A0 (en) Solid pharmaceutical dosage form
IL214036A0 (en) Pharmaceutical composition for inhalation
IL216256A0 (en) A pharmaceutical composition
EP2379077A4 (en) PHARMACEUTICAL COMPOSITION
ZA200903854B (en) A gastroretentive pharmaceutical dosage form
PL2285413T3 (pl) Kompozycja farmaceutyczna
ZA200903858B (en) Pharmaceutical dosage form
GB0712389D0 (en) A Pharmaceutical composition
EP2450038A4 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF DIABETIC NEUROPATHY AND MANUFACTURING AND USE METHODS
GB201009713D0 (en) A pharmaceutical composition for treating diabetes and preparation methods thereof
BR112012004215A2 (pt) "dispositivo para dispensação de um material dental"
BRPI1016086A2 (pt) aparelho para a liberação de um material volátil
BRPI0924296A2 (pt) composição farmacêutica para tratar do câncer compreendendo um composto conjugado de cloro e6-ácido fólico e quitosana
ZA201204341B (en) Pharmaceutical composition for treating gutaneous burns
EP2382992A4 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF ADIPOSITAS OR DIABETES
ZA201201894B (en) Pharmaceutical combination for treating tumor
GB0919650D0 (en) Pharmaceutical composition
PL384259A1 (pl) Kompozycja farmaceutyczna do leczenia chorób skórnych
TWI372054B (en) A pharmaceutical composition for preventing or treating cardiovascular disease
ZA200903855B (en) A pharmaceutical dosage form
GB0920933D0 (en) Agent for treating disease

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed